Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL656654 | 0.87 | MAPT (0.57) | SYKLMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL655819 | 0.82 | SYK (0.52) | SYKEGFRLMNAMAPTSMN1; SMN2 | |
| SCHEMBL27612398 | 0.82 | SYK (0.65) | SYKEGFR | |
| SCHEMBL27632158 | 0.82 | SYK (0.65) | SYKEGFR | |
| SCHEMBL655299 | 0.78 | SYK (0.67) | SYKEGFRSMN1; SMN2 | |
| SCHEMBL27612687 | 0.78 | SYK (0.60) | SYKEGFRAURKA | |
| SCHEMBL27612665 | 0.77 | SYK (0.56) | SYKEGFR | |
| SCHEMBL654713 | 0.77 | ALDH1A1 (0.62) | SYKLMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL656182 | 0.77 | SYK (0.74) | SYKEGFRAURKAMAPK8AURKB | |
| SCHEMBL27612772 | 0.75 | SYK (0.56) | SYKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |